

1 **Diagnostic Performance and Characteristics of Anterior Nasal Collection for the SARS-**  
2 **CoV-2 Antigen Test: A Prospective Study in Japan**

3

4 Yuto Takeuchi,<sup>a,b</sup> Yusaku Akashi,<sup>b,c,#</sup> Daisuke Kato,<sup>d</sup> Miwa Kuwahara,<sup>d</sup> Shino Muramatsu,<sup>d</sup>

5 Atsuo Ueda,<sup>e</sup> Shigeyuki Notake,<sup>e</sup> Koji Nakamura,<sup>e</sup> Hiroichi Ishikawa,<sup>f</sup> Hiromichi Suzuki,<sup>a,b,g</sup>

6

7 <sup>a</sup>Department of Infectious Diseases, University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan

8 <sup>b</sup>Division of Infectious Diseases, Department of Medicine, Tsukuba Medical Center Hospital,

9 Tsukuba, Ibaraki, Japan

10 <sup>c</sup>Akashi Internal Medicine Clinic, Kashiwara, Osaka, Japan

11 <sup>d</sup>Denka Co., Ltd. Gosen site, Reaserch & Development Division, Reagent R&D Department,

12 Gosen, Niigata, Japan

13 <sup>e</sup>Department of Clinical Laboratory, Tsukuba Medical Center Hospital, Tsukuba, Ibaraki,

14 Japan

15 <sup>f</sup>Department of Respiratory Medicine, Tsukuba Medical Center Hospital, Tsukuba, Ibaraki,

16 Japan

17 <sup>s</sup>Department of Infectious Diseases, Faculty of Medicine, University of Tsukuba, Tsukuba,

18 Ibaraki, Japan

19

20 Running Head: SARS-CoV-2 antigen test with anterior nasal sample

21

22 #Address correspondence to Yusaku Akashi, [yusaku-akashi@umin.ac.jp](mailto:yusaku-akashi@umin.ac.jp)

23 Author order was determined in order of increasing seniority.

24

25 ABSTRACT

26 We conducted a prospective study in Japan to evaluate the diagnostic performance of the  
27 antigen test QuickNavi-COVID19 Ag using anterior nasal samples and to compare the  
28 degrees of coughs or sneezes induction and the severity of pain between anterior nasal  
29 collection and nasopharyngeal collection. A total of 862 participants were included in the  
30 analysis. In comparison to the findings of reverse transcription PCR using nasopharyngeal  
31 samples, the antigen test using anterior nasal samples showed 72.5% sensitivity (95%  
32 confidence interval [CI]: 58.3%-84.1%) and 100% specificity (95% CI: 99.3%-100%).  
33 Anterior nasal collection was associated with a significantly lower degree of coughs or  
34 sneezes induction and the severity of pain in comparison to nasopharyngeal collection ( $p <$   
35 0.001). The antigen test using anterior nasal samples showed moderate sensitivity but was  
36 less painful and induced fewer coughs or sneezes.

37

38 INTRODUCTION

39 The laboratory diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-  
40 2) includes nucleic acid amplification tests (NAATs), antigen tests, and antibody tests (1).  
41 Antigen tests are generally less sensitive than NAATs for detecting SARS-CoV-2 but are  
42 relatively inexpensive, and most can be performed at the point of care (2).

43 The diagnostic performance of antigen test of nasopharyngeal samples has been evaluated,  
44 and the reported specificity is consistently high > 97%, while sensitivity ranges from 0% to  
45 94% (2). We previously evaluated the performance of an antigen test, QuickNavi-COVID19  
46 Ag (Denka Co., Ltd., Tokyo, Japan), using nasopharyngeal samples from 1186 participants  
47 (3). The overall sensitivity and specificity were 86.7% (95% confident interval [CI]: 78.6%-  
48 92.5%) and 100% (95% CI: 99.7%-100%), respectively, and the sensitivity for symptomatic  
49 participants was 91.7% (95% CI: 82.7%-96.9%) (3).

50 In recent studies, the sensitivity of anterior nasal samples was reported to be comparable  
51 to that of nasopharyngeal samples for NAATs (4, 5). Anterior nasal collection was reported  
52 to be less painful than nasopharyngeal collection (6) and may cause less droplet dispersal.  
53 These benefits are also expected in antigen tests but have yet to be fully evaluated.

54        We prospectively evaluated the diagnostic performance of the QuickNavi-COVID19 Ag  
55        test using anterior nasal samples and compared the degrees of coughs or sneezes induction  
56        and the severity of pain between anterior nasal collection and nasopharyngeal collection.

57

## 58 MATERIALS AND METHODS

59 We conducted the present prospective study between October 7, 2020 and January 9, 2021,  
60 at a drive-through PCR center where participants were referred from a local public health  
61 center and 97 primary care facilities in Tsukuba, Japan. After receiving the participants'  
62 informed consent, additional anterior nasal samples for the antigen test were collected and  
63 their clinical information was obtained. Cases with no clinical data were excluded from this  
64 study. In cases where participants enrolled in the current study more than once, only the first  
65 evaluation was included in this study. The present study was approved by the ethics  
66 committee of Tsukuba Medical Center Hospital (approval number: 2020-033).

67

### 68 **Sample collection and the antigen test procedure**

69 We simultaneously obtained an anterior nasal sample for the antigen test and a  
70 nasopharyngeal sample for the PCR examination. All samples were obtained with  
71 FLOQSwabs (Copan Italia S.p.A., Brescia, Italy).

72 The anterior nasal sample was initially collected according to the manufacturer's  
73 instructions. Namely, a nasopharyngeal-type flocked (NP-type) swab was inserted to 2 cm  
74 depth in one nasal cavity, rotated five times, and held in place for five seconds. The antigen

75 test using the QuickNavi-COVID19 Ag kit was performed immediately after anterior nasal  
76 collection and the result was obtained by the visual interpretation of each examiner.

77 A nasopharyngeal sample was subsequently collected with an NP-type swab according to  
78 a previously described procedure (7) and was diluted in 3 mL of Universal Transport Medium  
79 (UTM) (Copan Italia S.p.A., Brescia, Italy). The UTM was transferred to an in-house  
80 microbiology laboratory located next to the drive-through sample-collecting site of the PCR  
81 center within an hour of sample collection.

82

### 83 **SARS-CoV-2 detection using reverse transcription PCR**

84 After the arrival of the UTM samples, purification and RNA extraction were performed  
85 with magLEAD 6gC (Precision System Science Co., Ltd., Chiba, Japan) from 200  $\mu$ L  
86 aliquots of UTM for in-house reverse transcription (RT)-PCR on the same day as sample  
87 collection. RNA was eluted in 100  $\mu$ L and stored at -80 °C after the in-house RT-PCR test.  
88 The eluted samples were transferred to Denka Co., Ltd., every week for a reference real-time  
89 RT-PCR test on Applied Biosystems QuantStudio 3 (Thermo Fisher Scientific Inc., Waltham,  
90 MA, USA) using a QuantiTect Probe RT-PCR Kit (QIAGEN Inc., Germantown, MD, USA)  
91 and primer/probe N and N2 set (8).

92 The presence or absence of SARS-CoV-2 was defined by the results of the reference real-  
93 time RT-PCR test. However, if discordance existed between the reference real-time RT-PCR  
94 test and the in-house RT-PCR test, a re-evaluation was performed with an Xpert Xpress  
95 SARS-CoV-2 and GeneXpert System (Cepheid, Sunnyvale, CA, USA), the results of which  
96 provided the final judgment.

97

98 **The degrees of coughs or sneezes and the severity of pain induced by the sample**  
99 **collection procedure**

100 The degrees of coughs or sneezes and the severity of pain caused by the insertion of the  
101 swab into the anterior nasal cavity and nasopharynx in the same participant were assessed.  
102 Examiners rated the degrees of coughs or sneezes induction from the following four  
103 categories: “None”, “Small, 1-2 times”, “Loud, 1-2 times” and “Loud, multiple times”. The  
104 severity of pain was evaluated with a five-point scale (Pain score), with 1 being "no pain"  
105 and 5 being "worst imaginable pain," and the participants were asked to report a number from  
106 the scale.

107



108 **The comparison of SARS-CoV-2 viral loads between different sample collection sites**  
109 **and swab types**

110 We conducted an additional experiment to evaluate whether the viral loads differed  
111 between sample collection sites and swab types between January 8 and 19, 2021. After  
112 receiving the participants' informed consent, two anterior nasal samples were obtained from  
113 the participants for whom a nasopharyngeal sample had already tested positive for SARS-  
114 CoV-2. Two anterior nasal swab samples were collected from each nostril using one with a  
115 NP-type swab and the other with an oropharyngeal-type flocced (OP-type) swab. These  
116 sample collections were performed on the same day.

117 The samples were diluted in 3 mL of UTM, and stored at -80°C. After several days of  
118 storage, the samples were thawed, and purification and RNA extraction were performed  
119 according to the above-described method. The viral concentrations in samples were  
120 quantified with the following procedure. The calibration curves were generated with 5, 50,  
121 and 500 copies/reaction of positive control (EDX SARS-CoV-2 Standard; Bio-Rad  
122 Laboratories, Inc., Hercules, CA, USA). Quantitative RT-PCR was performed on a  
123 LightCycler 96 System (Roche, Basel, Switzerland) using a THUNDERBIRD Probe One-  
124 step qRT-PCR Kit (TOYOBO Co. Ltd., Osaka, Japan) with a primer/probe N2 set.

125

126 **Statistical analyses**

127 The sensitivity, specificity, positive predictive value (PPV), and negative predictive value  
128 (NPV) of QuickNavi-COVID19 Ag and their 95% confidence intervals (CIs) were calculated  
129 with the Clopper and Pearson method. The viral loads according to collection sites and swab  
130 types were compared by the Wilcoxon signed-rank test with Holm correction. The degrees  
131 of coughs or sneezes induction and the pain score were also compared between the two  
132 different collection procedures using the the McNemar-Bowker test and the Wilcoxon  
133 signed-rank test, respectively. *P* values of  $< 0.05$  were considered to indicate statistical  
134 significance. All statistical analyses were conducted using the R 3.5.2 software program (The  
135 R Foundation, Vienna, Austria).

136

## 137 RESULTS

### 138 **Viral loads in different sample collection sites and swab types**

139 In 32 identical SARS-CoV-2 positive cases, we evaluated the SARS-CoV-2 viral loads of  
140 nasopharyngeal samples (NPS), anterior nasal samples with NP-type swabs (AWN), and  
141 anterior nasal samples with OP-type swabs (AWO) (Fig. 1). The median viral loads for NPS,  
142 AWN, and AWO were 53,560 (interquartile range [IQR]: 605-608,050), 1,792 (IQR: 7-  
143 81,513), and 6,369 (IQR: 7-97,535), respectively. With the NPS as a reference, the PCR-  
144 positive rate for AWN was 84.4% (27/32; 95% CI: 67.2%-94.7%), while that for AWO was  
145 81.3% (26/32; 95% CI: 63.6%-92.8%). In comparison to NPS, the viral load was significantly  
146 lower with AWN ( $p < 0.001$ ) and AWO ( $p < 0.001$ ), but there was no significant difference  
147 between AWN and AWO ( $p = 0.61$ ). The viral loads and Ct values for all samples are  
148 described in Table S1a and Table S1b.

149

### 150 **Demographic data of study population**

151 A total of 876 participants were screened for the evaluation. Most samples were obtained  
152 at the drive-through PCR center, and only 17 were obtained after hospitalization. We

153 excluded the participants who underwent duplicate tests (n=7) or for whose clinical  
154 information were lacking (n=7). Finally, 862 participants were included in the analysis.

155 Among the 862 participants, SARS-CoV-2 was detected in 50 (5.8%) on nasopharyngeal  
156 samples by the reference real-time RT-PCR test. There was one discordant sample that was  
157 positive on the in-house RT-PCR test and negative on the reference real-time RT-PCR test.

158 The Xpert Xpress SARS-CoV-2 test provided a positive result for the sample (cycle threshold  
159 [Ct] values for E and N2 targets: 0.0 and 39.8, respectively); thus, 51 (5.9%) participants  
160 were finally considered positive for SARS-CoV-2. The discordant sample was obtained from  
161 a participant who had been diagnosed with COVID-19 one month before the current  
162 evaluation and who was referred to the PCR center due to refractory respiratory symptoms.

163 All 51 participants who were positive for SARS-CoV-2 were symptomatic (Table 1a); their  
164 characteristics are described in Table 1b. The most common symptom was fever (80.4%),  
165 followed by cough or sputum production (60.8%), sore throat (37.3%), runny nose or nasal  
166 congestion (35.5%), and loss of taste or smell (27.5%).

167

168 **Diagnostic performance of QuickNavi-COVID19 Ag using anterior nasal samples**

169 Of the 51 participants who were found to be SARS-CoV-2-positive by the RT-PCR test,  
170 37 participants were found to be positive with the antigen test with anterior nasal samples  
171 (Table 2). Among the 811 SARS-CoV-2-negative participants, all participants were found to  
172 be negative with the antigen test (Table 2). The concordance rate between the antigen test  
173 and RT-PCR was thus 98.4% (95% CI: 97.3%-99.1%). The sensitivity, specificity, PPV, and  
174 NPV were 72.5% (95% CI: 58.3%-84.1%), 100% (95% CI: 99.3%-100%), 100% (95%CI:  
175 86.2%-100%), and 98.3% (95%CI: 97.2%-99.1%), respectively (Table 2).

176

### 177 **Comparison of degrees of coughs or sneezes induction and the severity of pain between** 178 **anterior nasal and nasopharyngeal sample collection**

179 The degrees of coughs or sneezes induced by sample collection was measured in 784  
180 participants (Fig. 2). Coughing or sneezing was observed in 149 (19.0%) of anterior nasal  
181 collections and in 316 (40.3%) of nasopharyngeal collection. When coughs or sneezes  
182 occurred in anterior nasal collection, their degrees were significantly lower than in  
183 nasopharyngeal collection ( $p < 0.001$ ).

184 The pain score was obtained from 90 participants (Fig. 3). Fifty-seven participants (63.3%)  
185 reported no pain in anterior nasal collection. The median pain score of anterior nasal

186 collection and nasopharyngeal collection was 1 (IQR: 1-2) and 3 (IQR: 2-4), respectively. In  
187 comparison to nasopharyngeal collection, anterior nasal collection was significantly less  
188 painful ( $p < 0.001$ ).

189 DISCUSSION

190 The QuickNavi-COVID19 Ag test using anterior nasal samples showed 72.5% sensitivity  
191 and 100% specificity. In comparison to nasopharyngeal collection, anterior nasal collection  
192 was less painful and was associated with fewer coughs or sneezes. In addition, the study  
193 demonstrated that the viral load of anterior nasal samples was significantly lower than that  
194 of nasopharyngeal samples. Meanwhile, the swab types did not influence the viral load of  
195 anterior nasal samples.

196 In the current study, anterior nasal samples provided a lower antigen test sensitivity than  
197 our previous study evaluating nasopharyngeal samples (3). The sensitivity of antigen tests is  
198 largely influenced by the viral load in collected samples (9–12). The QuickNavi-COVID19  
199 Ag test could detect SARS-CoV-2 in almost all samples with Ct values < 30, and in 18.8%  
200 of samples with Ct values > 30 (3). The viral load may vary between collection sites (13),  
201 and this study recognized the viral load of samples was significantly lower when they were  
202 collected from the anterior nasal cavity (Fig. 1). This lower viral load in anterior nasal  
203 samples could explain the decreased sensitivity. On the other hand, the QuickNavi-COVID19  
204 Ag test provided 100% specificity in both the present study and our previous study (3).  
205 Although it is necessary to verify whether similar results can be obtained in other settings,

206 false positives should be avoided to prevent unnecessary additional testing and inappropriate  
207 isolation measures (14).

208 We observed that anterior nasal collection caused fewer coughs or sneezes in comparison  
209 to nasopharyngeal sample collection (Fig. 2). Notably, anterior nasal collection induced  
210 coughs or sneezes in only 19% of participants. Coughs or sneezes generate droplets and  
211 prolong their dispersal by forming multiphase turbulent gas clouds (15), which leads to  
212 greater droplet exposure. SARS-CoV-2 is mainly transmitted through droplets (16); thus,  
213 anterior nasal collection, which was associated with fewer coughs or sneezes induction, may  
214 reduce the transmission risk among healthcare providers.

215 Anterior nasal collection was less painful (Fig. 3), with more than half of the participants  
216 reporting no pain from the procedure. Nasopharyngeal collection is an uncomfortable and  
217 painful experience (6) and may discourage patients from receiving tests. Besides,  
218 nasopharyngeal collection may not be applicable if patients have a history of recent nasal  
219 trauma or surgery, remarkable nasal septum deviation, or marked coagulopathy (7). Despite  
220 the decreased sensitivity, when NAATs are not readily available, an antigen test with anterior  
221 nasal samples may be an option in these clinical contexts.



222 The selection of swab type influences the uptake, extraction and recovery efficiency of the  
223 collected sample (17, 18). In this study, we compared two flocked swabs with different tip  
224 sizes (NP-type and OP-type swab). There was no significant difference in the viral load of  
225 the samples collected with the two types of swabs; however, the OP-type swab has a larger  
226 tip and seemed to handle a larger amount of samples collected. A previous study suggested  
227 that the efficiency of sample release was not associated with the absorbed volume (19), which  
228 could explain the result in this study.

229 The present study was associated with some limitations. First, the samples used for the  
230 reference real-time RT-PCR test were frozen and transported. Although the samples were  
231 frozen at -80°C, the viral loads may have been decreased during the storage and transport  
232 process. Nevertheless, in the case of discrepancy with in-house PCR, re-evaluation was  
233 performed and did not affect the calculation of the sensitivity of the antigen test. Second,  
234 asymptomatic SARS-CoV-2 positive patients were unintentionally not included in this study.  
235 Further study is required to evaluate the clinical performance of the antigen test in those  
236 patients. Finally, this study was conducted at a single center, although participants were  
237 referred from multiple primary facilities. Further research should be conducted to assess the  
238 generalizability of the findings.

239 In conclusion, the QuickNavi-COVID19 Ag test with an anterior nasal sample showed  
240 100% specificity; however, the sensitivity in the detection of SARS-CoV-2 was lower in  
241 comparison to the QuickNavi-COVID19 Ag test with nasopharyngeal samples. Anterior  
242 nasal collection was less invasive and induced fewer coughs or sneezes, which may be more  
243 comfortable for the patient and may reduce the risk of droplet exposure to healthcare workers.  
244

245 ACKNOWLEDGEMENTS

246 We thank Mrs. Yoko Ueda, Mrs. Mio Matsumoto, Dr. Yumi Hirose and the staff in the  
247 Department of Clinical Laboratory of Tsukuba Medical Center Hospital for their intensive  
248 support of this study. We thank all of the medical institutions for providing their patients'  
249 clinical information. Mrs. Yoko Ueda and Mrs. Mio Matsumoto significantly contributed to  
250 creating the database of this study.

251 Denka Co., Ltd., provided fees for research expenses and the QuickNavi-COVID19 Ag  
252 kits without charge. Hiromichi Suzuki received a lecture fee from Otsuka Pharmaceutical  
253 Co., Ltd., regarding this study. Daisuke Kato, Miwa Kuwahara and Shino Muramatsu belong  
254 to Denka Co., Ltd., the developer of the QuickNavi-COVID19 Ag.

255

256 REFERENCES

- 257 1. World Health Organization. 2020. Diagnostic testing for SARS-CoV-2: interim  
258 guidance, 11 September 2020. <https://apps.who.int/iris/handle/10665/334254>.  
259 Accessed 24 February 2021.

- 260 2. World Health Organization. 2020. Antigen-detection in the diagnosis of SARS-CoV-  
261 2 infection using rapid immunoassays: interim guidance, 11 September 2020.  
262 <https://apps.who.int/iris/handle/10665/334253>. Accessed 24 February 2021.
- 263 3. Takeuchi Y, Akashi Y, Kato D, Kuwahara M, Muramatsu S, Ueda A, Notake S,  
264 Nakamura K, Ishikawa H, Suzuki H. 2021. The evaluation of a newly developed  
265 antigen test (QuickNavi<sup>TM</sup>-COVID19 Ag) for SARS-CoV-2: A prospective  
266 observational study in Japan. medRxiv  
267 <https://doi.org/10.1101/2020.12.27.20248876>.
- 268 4. Péré H, Podglajen I, Wack M, Flamarion E, Mirault T, Goudot G, Hauw-Berlemont  
269 C, Le L, Caudron E, Carrabin S, Rodary J, Ribeyre T, Bélec L, Veyer D. 2020. Nasal  
270 Swab Sampling for SARS-CoV-2: a Convenient Alternative in Times of  
271 Nasopharyngeal Swab Shortage. J Clin Microbiol [https://doi.org/10.1128/jcm.00721-](https://doi.org/10.1128/jcm.00721-20)  
272 20.
- 273 5. Tu Y-P, Jennings R, Hart B, Cangelosi GA, Wood RC, Wehber K, Verma P, Vojta  
274 D, Berke EM. 2020. Swabs Collected by Patients or Health Care Workers for SARS-  
275 CoV-2 Testing. N Engl J Med 383:494–496.

- 276 6. Frazee BW, Rodríguez-Hoces de la Guardia A, Alter H, Chen CG, Fuentes EL,  
277 Holzer AK, Lolas M, Mitra D, Vohra J, Dekker CL. 2018. Accuracy and Discomfort  
278 of Different Types of Intranasal Specimen Collection Methods for Molecular  
279 Influenza Testing in Emergency Department Patients. *Ann Emerg Med* 71:509-  
280 517.e1.
- 281 7. Marty FM, Chen K, Verrill KA. 2020. How to Obtain a Nasopharyngeal Swab  
282 Specimen. *N Engl J Med* 382:e76.
- 283 8. Shirato K, Nao N, Katano H, Takayama I, Saito S, Kato F, Katoh H, Sakata M,  
284 Nakatsu Y, Mori Y, Kageyama T, Matsuyama S, Takeda M. 2020. Development of  
285 genetic diagnostic methods for detection for novel coronavirus 2019(nCoV-2019) in  
286 Japan. *Jpn J Infect Dis* 73:304–307.
- 287 9. Hirotsu Y, Maejima M, Shibusawa M, Amemiya K, Nagakubo Y, Hosaka K, Sueki  
288 H, Hayakawa M, Mochizuki H, Tsutsui T, Kakizaki Y, Miyashita Y, Omata M.  
289 2021. Prospective Study of 1,308 Nasopharyngeal Swabs from 1,033 Patients using  
290 the LUMIPULSE SARS-CoV-2 Antigen Test: Comparison with RT-qPCR. *Int J*  
291 *Infect Dis* <https://doi.org/10.1016/j.ijid.2021.02.005>.

- 292 10. Aoki K, Nagasawa T, Ishii Y, Yagi S, Okuma S, Kashiwagi K, Maeda T, Miyazaki  
293 T, Yoshizawa S, Tateda K. 2021. Clinical validation of quantitative SARS-CoV-2  
294 antigen assays to estimate SARS-CoV-2 viral loads in nasopharyngeal swabs. *J*  
295 *Infect Chemother* <https://doi.org/10.1016/j.jiac.2020.11.021>.
- 296 11. Salvagno GL, Gianfilippi G, Bragantini D, Henry BM, Lippi G. 2021. Clinical  
297 assessment of the Roche SARS-CoV-2 rapid antigen test. *Diagnosis*  
298 <https://doi.org/10.1515/dx-2020-0154>.
- 299 12. Merino P, Guinea J, Muñoz-Gallego I, González-Donapetry P, Galán JC, Antona N,  
300 Cilla G, Hernández-Crespo S, Díaz-de Tuesta JL, Torrella AG, González-Romo F,  
301 Escribano P, Sánchez-Castellano MÁ, Sota-Busselo M, Delgado-Iribarren A, García  
302 J, Cantón R, Muñoz P, Folgueira MD, Cuenca-Estrella M, Oteo-Iglesias J, Medrano  
303 S, Pérez A, Galar A, Martínez-Expósito O, Alejo-Cancho I, Martín-Higuera MC,  
304 Rolo M, Estévez MJ, Bravo T, Vicente D, Montes M. 2021. Multicenter evaluation  
305 of the Panbio™ COVID-19 rapid antigen-detection test for the diagnosis of SARS-  
306 CoV-2 infection. *Clin Microbiol Infect* <https://doi.org/10.1016/j.cmi.2021.02.001>.
- 307 13. Lee RA, Herigon JC, Benedetti A, Pollock NR, Denkinger CM. 2021. Performance  
308 of Saliva, Oropharyngeal Swabs, and Nasal Swabs for SARS-CoV-2 Molecular

- 309           Detection: A Systematic Review and Meta-analysis. *J Clin Microbiol*
- 310           <https://doi.org/10.1128/jcm.02881-20>.
- 311    14.    Ogawa T, Fukumori T, Nishihara Y, Sekine T, Okuda N, Nishimura T, Fujikura H,
- 312           Hirai N, Imakita N, Kasahara K. 2020. Another false-positive problem for a SARS-
- 313           CoV-2 antigen test in Japan. *J Clin Virol* 131:104612.
- 314    15.    Bourouiba L. 2020. Turbulent Gas Clouds and Respiratory Pathogen Emissions:
- 315           Potential Implications for Reducing Transmission of COVID-19. *JAMA - J Am Med*
- 316           *Assoc* 323:1837–1838.
- 317    16.    World Health Organization. 2020. Transmission of SARS-CoV-2 : implications for
- 318           infection prevention precautions. [https://www.who.int/publications/i/item/modes-of-](https://www.who.int/publications/i/item/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations)
- 319           [transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-](https://www.who.int/publications/i/item/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations)
- 320           [recommendations](https://www.who.int/publications/i/item/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations). Accessed 24 February 2021.
- 321    17.    Kahamba TR, Noble L, Stevens W, Scott L. 2020. Comparison of three
- 322           nasopharyngeal swab types and the impact of physiochemical properties for optimal
- 323           SARS-CoV-2 detection. medRxiv <https://doi.org/10.1101/2020.10.21.20206078>.
- 324    18.    Bruijns BB, Tiggelaar RM, Gardeniers H. 2018. The Extraction and Recovery
- 325           Efficiency of Pure DNA for Different Types of Swabs. *J Forensic Sci* 63:1492–1499.

326 19. Zasada AA, Zacharczuk K, Woźnica K, Główna M, Ziółkowski R, Malinowska E.

327 2020. The influence of a swab type on the results of point-of-care tests. *AMB*

328 *Express* <https://doi.org/10.1186/s13568-020-00978-9>.

329

330



331 Figure Legends

332 **FIG 1.** Comparison of SARS-CoV-2 viral loads between each collection site and swab type.

333 The set of viral loads in the same participant is represented by connected lines. The viral

334 loads were compared by the Wilcoxon signed-rank test, and *P* values are corrected with Holm

335 correction. NP swab, nasopharyngeal-type swab; OP swab, oropharyngeal-type swab; CI,

336 confidence interval; IQR, interquartile range.

337

338 **FIG 2.** Degrees of coughs or sneezes induced by anterior nasal and nasopharyngeal collection.

339 The degrees of coughing or sneezing following swab insertion was compared between

340 anterior nasal collection and nasopharyngeal collection in the same participant (*n* = 784). The

341 degrees were rated on a four-point scale. The McNemar-Bowker test was used for the

342 comparison.

343

344 **FIG 3.** The pain score in anterior nasal collection and nasopharyngeal collection. The

345 severity of pain at swab insertion was assessed on a five-point scale, from 1 to 5 (Pain score).

346 The pain score for each collection method was obtained from the same participant (*n* = 90).

347 The comparison of the pain scores with the two collection procedures was performed with  
348 the Wilcoxon signed-rank test.

Table 1a. Demographic data of the whole study population and cases infected with SARS-CoV-2

	Total	SARS-CoV-2	
		Positive	Negative
N	862	51	811
Age (years, median [IQR])	36.0 [24.0, 48.0]	43.0 [30.0, 57.5]	35.0 [23.0, 47.0]
<18 years	106 (12.3)	2 (3.9)	104 (12.8)
18-64 years	678 (78.7)	44 (86.3)	634 (78.2)
≥ 65 years	78 (9.0)	5 (9.8)	73 (9.0)
Sex (Female)	383 (44.4)	19 (37.3)	364 (44.9)
Asymptomatic participants	72 (8.4)	0 (0.0)	72 (8.9)
Symptomatic participants	790 (91.6)	51 (100)	739 (91.1)

Table 1b. Characteristics of symptomatic participants and cases infected with SARS-CoV-2

	Total	SARS-CoV-2	
		Positive	Negative
N	790	51	739
Days from symptom onset to sample collection [IQR]	2.0 [1.0, 3.0]	3.0 [2.0, 5.0]	2.0 [1.0, 3.0]
Signs and symptoms			
Fever	628 (79.5)	41 (80.4)	587 (79.4)
Cough/sputum production	255 (32.3)	31 (60.8)	224 (30.3)
Runny nose/nasal congestion	185 (23.4)	18 (35.3)	167 (22.6)
Loss of taste or smell	32 (4.1)	14 (27.5)	18 (2.4)
Dyspnea	7 (0.9)	2 (3.9)	5 (0.7)
Fatigue	105 (13.3)	10 (19.6)	95 (12.9)
Diarrhea	48 (6.1)	1 (2.0)	47 (6.4)
Sore throat	210 (26.6)	19 (37.3)	191 (25.8)
Headache	121 (15.3)	11 (21.6)	110 (14.9)


349

350

Table 2. Clinical performance of antigen test using anterior nasal samples

		PCR (nasopharyngeal samples)	
		Positive	Negative
Antigen test	Positive	37	0
	Negative	14	811
Sensitivity		72.5 (58.3-84.1)	
Specificity		100 (99.3-100)	
Positive predictive value		100 (86.2-100)	
Negative predictive value		98.3 (97.2-99.1)	

Sensitivity, specificity, positive predictive value, and negative predictive value are provided with 95% confidence intervals.



	Nasopharyngeal sample	Anterior nasal sample with NP-type swab	Anterior nasal sample with OP-type swab
PCR positive rate, % (95% CI)	reference	84.4 (67.2-94.7)	81.2 (63.6-92.8)
Median viral load, copies/mL [IQR]	53,560 [605 - 608,050]	1,792 [7 - 81,513]	6,369 [7 - 97,535]

